Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients

被引:30
作者
Brindisi, Marie-Claude [1 ,2 ,3 ]
Brondel, Laurent [1 ,2 ]
Meillon, Sophie [1 ,2 ]
Barthet, Sophie [1 ,2 ]
Grall, Sylvie [1 ,2 ]
Fenech, Claire [1 ,2 ]
Lienard, Fabienne [1 ,2 ]
Schlich, Pascal [1 ,2 ]
Astruc, Karine [4 ]
Mouillot, Thomas [1 ,5 ]
Jacquin-Piques, Agnes [1 ,6 ]
Leloup, Corinne [1 ,2 ]
Verges, Bruno [3 ]
Penicaud, Luc [1 ,2 ,7 ]
机构
[1] CNRS UMR 6265, Ctr Sci Gout & Alimentat, F-21000 Dijon, France
[2] INRA UMR 1324, Ctr Sci Gout & Alimentat, F-21000 Dijon, France
[3] Dijon Univ Hosp, Diabet & Endocrinol Unit, F-21000 Dijon, France
[4] Epidemiol & Hosp Hygene Unit, Dijon, France
[5] Dijon Univ Hosp, Gastroenterol Dept, F-21000 Dijon, France
[6] Dijon Univ Hosp, Neurol Dept, F-21000 Dijon, France
[7] CNRS, Stromalab ERL 5311, F-31432 Toulouse, France
关键词
GLP1-Analogue; Diabetes; Food behavior; Taste perception; GLUCAGON-LIKE PEPTIDE-1; SUPPRESSES GHRELIN; CNS RESPONSES; LIRAGLUTIDE; ANALOG; SWEET; QUESTIONNAIRE; ASSOCIATION; ACTIVATION; SECRETION;
D O I
10.1016/j.dsx.2019.06.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: GLP-1 analogues decrease food intake and have great promise for the fight against obesity. Little is known about their effects on food hedonic sensations and taste perception in poor controlled patients with type 2 diabetes (T2D). Materials and methods: Eighteen T2D patients with BMI >= 25 kg/m(2) and poor controlled glycemia were studied before and after 3 months of treatment with Liraglutide. Detection thresholds for salty, sweet and bitter tastes, optimal preferences, olfactory liking, wanting and recalled liking for several food items were assessed. Subjects also answered questionnaires to measure their attitudes to food. Results: T2D patients had a significant decrease in bodyweight and HbA1c after treatment with Liraglutide. Liraglutide improved gustative detection threshold of sweet flavors, and decreased wanting for sweet foods and recalled liking for fatty foods. It also led to a decrease in feelings of hunger. Conclusions: Liraglutide increases sensitivity to sweet tastes and decreases pleasure responses for fatty foods in poor controlled T2D patients, and is of particular interest in the understanding of the mechanisms of weight loss. (C) 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:2489 / 2494
页数:6
相关论文
共 35 条
[1]  
[Anonymous], 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138
[2]  
[Anonymous], DIABETES METAB S1
[3]   Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].
Astrup, Arne ;
Rossner, Stephan ;
Van Gaal, Luc ;
Rissanen, Aila ;
Niskanen, Leo ;
Al Hakim, Mazin ;
Madsen, Jesper ;
Rasmussen, Mads F. ;
Lean, Michael E. J. .
LANCET, 2009, 374 (9701) :1606-1616
[4]   Food reward: Brain substrates of wanting and liking [J].
Berridge, KC .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1996, 20 (01) :1-25
[5]   Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity [J].
Blundell, John ;
Finlayson, Graham ;
Axelsen, Mads ;
Flint, Anne ;
Gibbons, Catherine ;
Kvist, Trine ;
Hjerpsted, Julie B. .
DIABETES OBESITY & METABOLISM, 2017, 19 (09) :1242-1251
[6]   Is There a Relationship Between Oral Health and Diabetic Neuropathy? [J].
Borgnakke, Wenche S. ;
Anderson, Patricia F. ;
Shannon, Carol ;
Jivanescu, Anca .
CURRENT DIABETES REPORTS, 2015, 15 (11)
[7]   Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors [J].
Daousi, C ;
Casson, IF ;
Gill, GV ;
MacFarlane, IA ;
Wilding, JPH ;
Pinkney, JH .
POSTGRADUATE MEDICAL JOURNAL, 2006, 82 (966) :280-284
[8]  
Darmon P, 2017, MED MALADIES METABOL, V11
[9]   Development of a questionnaire to assay recalled liking for salt, sweet and fat [J].
Deglaire, Amelie ;
Mejean, Caroline ;
Castetbon, Katia ;
Kesse-Guyot, Emmanuelle ;
Urbano, Christine ;
Hercberg, Serge ;
Schlich, Pascal .
FOOD QUALITY AND PREFERENCE, 2012, 23 (02) :110-124
[10]   The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].
Drucker, Daniel J. ;
Nauck, Michael A. .
LANCET, 2006, 368 (9548) :1696-1705